BridgeBio Pharma Inc

+0.15 (+1.65%)
Earnings Announcements

BridgeBio Announces Early Data For BBP-812, Investigational AAV9 Gene Therapy For Canavan Disease

Published: 06/22/2022 12:02 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Announces Early Positive Data for Bbp-812, Its Investigational Aav9 Gene Therapy for Canavan Disease.
Bridgebio Pharma Inc - Initial Pharmacodynamic Results for Two Participants Show Unprecedented Decreases in N-acetylaspartate (naa) in Brain and Urine.
Bridgebio Pharma - Results First Reported Demonstration of Rapid, Robust Treatment Changes in Key Disease Markers Associated With Severity of Disease.
Bridgebio Pharma Inc - From a Safety Standpoint, Iv Infusions of Bbp-812 Have Been Well-tolerated.
Bridgebio Pharma Inc - to Date, No Participants Have Experienced a Treatment-related Serious Adverse Event.
Revenue is expected to be $41.92 Million
Adjusted EPS is expected to be -$0.60

Next Quarter Revenue Guidance is expected to be $19.16 Million
Next Quarter EPS Guidance is expected to be -$0.86

More details on our Analysts Page.